272 results on '"Ballinger M"'
Search Results
52. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
53. Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma
54. Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
55. LBA1 - Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC
56. 1470P - Fractional polynomial network meta-analysis: A different approach to indirectly assess the comparative efficacy of 2L+ cancer immunotherapy (CIT) treatments for metastatic NSCLC
57. 447TiP - The cancer molecular screening and therapeutics program (MoST): A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies
58. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs. docetaxel in patients with advanced NSCLC (POPLAR)
59. 14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)
60. 1310P - Survival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study
61. 1314P - Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK
62. 1313P - Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK
63. 1296O - Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study
64. 1295O - Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)
65. 96PD_PR - Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: Results from the randomized Phase II study POPLAR
66. 89PD - Results from OAK subgroup analyses: A randomized Phase III study of atezolizumab vs docetaxel in patients (pts) with advanced NSCLC
67. LBA44_PR - Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
68. 1109PD - Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma
69. Early postnatal GABAAreceptor modulation reverses deficits in neuronal maturation in a conditional neurodevelopmental mouse model of DISC1
70. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
71. Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease.
72. ChemInform Abstract: Differential Binding Energy: A Detailed Evaluation of the Influence of Hydrogen-Bonding and Hydrophobic Groups on the Inhibition of Thermolysin by Phosphorus-Containing Inhibitors.
73. Results of a Self-Absorption Study on the Versapor 3000 47-mm Filters for Radioactive Particulate Air Stack Sampling
74. Prostaglandin E2 Inhibits Alveolar Macrophage Phagocytosis of Candida Albicans by Cyclic AMP- and Epac-Dependent Effects on Actin Polymerization.
75. Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease
76. RESULTS OF INSPECTION AND CLEANING OF TWO RADIONUCLIDE AIR-SAMPLING SYSTEMS BASED ON THE REQUIREMENTS OF ANSI/HPS N13.1-1999
77. EVALUATION OF SAMPLING LOCATIONS FOR TWO RADIONUCLIDE AIR-SAMPLING SYSTEMS BASED ON THE REQUIREMENTS OF ANSI/HPS N13.1-1999
78. Minicomputer Capabilities Related to Meteorological Aspects of Emergency Response
79. Combustion aerosols formed during burning of radioactively contaminated materials: Experimental results
80. A computer code to estimate accidental fire and radioactive airborne releases in nuclear fuel cycle facilities: User's manual for FIRIN
81. Methods for describing airborne fractions of free fall spills of powders and liquids
82. Nuclear fuel cycle facility accident analysis handbook
83. Aerosols generated by spills of viscous solutions and slurries
84. S-Adenosylmethionine: a ‘poor man's coenzyme B12’ in the reaction of lysine 2,3-aminomutase
85. The Role of S ‐Adenosylmethionine as a Poor Man's Adenosylcobalamin in the Reaction of Lysine 2,3‐Aminomutase
86. Make the slides-to-digital process an easier one
87. Rewarming of the hypothermic rhesus monkey with electromagnetic radiation.
88. Selection of heregulin variants having higher affinity for the ErbB3 receptor by monovalent phage display.
89. Binding interaction of the heregulinbeta egf domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis.
90. Failure to demonstrate psychomotor effects of nitrous oxide oxygen exposure in dental assistants
91. Rapid induction of functional and morphological continuity between severed ends of mammalian or earthworm myelinated axons
92. Expansile lesion of the posterior maxilla in an adult male
93. Detection of Yellow Fever Viral RNA by Nucleic Acid Hybridization and Viral Antigen by Immunocytochemistry in Fixed Human Liver
94. Crayfish CNS: Minimal degenerative-regenerative changes after lesioning
95. Inherited and de novo germline TP53 mutations in adult-onset sarcoma
96. Impaired neonatal macrophage phagocytosis is not explained by overproduction of prostaglandin E2
97. Evolutionary maintenance of filovirus-like genes in bat genomes
98. Cardiac function and myocardial perfusion immediately following maximal treadmill exercise inside the MRI room
99. Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions
100. Validation of the Knowledge of Genome Sequencing (KOGS) scale in cancer patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.